Bristol/Merck’s Pargluva Cuts Glucose More Than Pioglitazone In Phase III
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Bristol-Myers Squibb/Merck’s Pargluva significantly reduces blood glucose in type 2 diabetics compared to Lilly/Takeda’s Actos, according to Phase III data presented June 12 at the American Diabetes Association annual meeting in San Diego.